Home » AstraZeneca Unit and WuXi in China Join to Form Joint Venture
AstraZeneca Unit and WuXi in China Join to Form Joint Venture
AstraZeneca’s MedImmune unit is joining with a Chinese pharmaceutical outsourcing company to develop an experimental treatment for autoimmune and inflammatory diseases, deepening the British drug developer’s presence in the world’s second-largest economy.
Businessweek
Businessweek
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May